Cost-effectiveness of collaborative care including PST and an antidepressant treatment algorithm for the treatment of major depressive disorder in primary care; A randomised clinical trial by IJff, M.A. (Marjoliek) et al.
BioMed CentralBMC Health Services Research
ssOpen AcceStudy protocol
Cost-effectiveness of collaborative care including PST and an 
antidepressant treatment algorithm for the treatment of major 
depressive disorder in primary care; a randomised clinical trial
Marjoliek A IJff*1,2, Klaas ML Huijbregts1,2, Harm WJ van Marwijk2,3, 
Aartjan TF Beekman1,2,4, Leona Hakkaart-van Roijen5, Frans F Rutten5, 
Jürgen Unützer6 and Christina M van der Feltz-Cornelis1,2,4
Address: 1Program Diagnosis and Treatment, Netherlands Institute of Mental Health and Addiction, Utrecht, The Netherlands, 2Institute for 
Research in Extramural Medicine, VU Medical Centre, Amsterdam, The Netherlands, 3Department of General Practice, VU Medical Centre, 
Amsterdam, The Netherlands, 4Department of Psychiatry, VU Medical Centre, Amsterdam, The Netherlands, 5Institute for Medical Technology 
Assessment, Erasmus Medical Centre, Rotterdam, The Netherlands and 6Center for Health Services Research, UCLA Neuropsychiatric Institute, Los 
Angeles, California, USA
Email: Marjoliek A IJff* - mijff@trimbos.nl; Klaas ML Huijbregts - khuijbregts@trimbos.nl; Harm WJ van Marwijk - hwj.vanmarwijk@vumc.nl; 
Aartjan TF Beekman - aartjanb@ggzba.nl; Leona Hakkaart-van Roijen - l.hakkaart-vanroijen@erasmusmc.nl; 
Frans F Rutten - f.rutten@erasmusmc.nl; Jürgen Unützer - unutzer@u.washington.edu; Christina M van der Feltz-Cornelis - cfeltz@trimbos.nl
* Corresponding author    
Abstract
Background: Depressive disorder is currently one of the most burdensome disorders worldwide. Evidence-based
treatments for depressive disorder are already available, but these are used insufficiently, and with less positive results
than possible. Earlier research in the USA has shown good results in the treatment of depressive disorder based on a
collaborative care approach with Problem Solving Treatment and an antidepressant treatment algorithm, and research
in the UK has also shown good results with Problem Solving Treatment. These treatment strategies may also work very
well in the Netherlands too, even though health care systems differ between countries.
Methods/design: This study is a two-armed randomised clinical trial, with randomization on patient-level. The aim of
the trial is to evaluate the treatment of depressive disorder in primary care in the Netherlands by means of an adapted
collaborative care framework, including contracting and adherence-improving strategies, combined with Problem Solving
Treatment and antidepressant medication according to a treatment algorithm. Forty general practices will be randomised
to either the intervention group or the control group. Included will be patients who are diagnosed with moderate to
severe depression, based on DSM-IV criteria, and stratified according to comorbid chronic physical illness. Patients in the
intervention group will receive treatment based on the collaborative care approach, and patients in the control group
will receive care as usual. Baseline measurements and follow up measures (3, 6, 9 and 12 months) are assessed using
questionnaires and an interview. The primary outcome measure is severity of depressive symptoms, according to the
PHQ9. Secondary outcome measures are remission as measured with the PHQ9 and the IDS-SR, and cost-effectiveness
measured with the TiC-P, the EQ-5D and the SF-36.
Discussion: In this study, an American model to enhance care for patients with a depressive disorder, the collaborative
care model, will be evaluated for effectiveness in the primary care setting. If effective across the Atlantic and across
different health care systems, it is also likely to be an effective strategy to implement in the treatment of major depressive
disorder in the Netherlands.
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The burden of depressive disorder on society and on indi-
vidual patients is enormous. The global burden of disease
study reports that unipolar major depressive disorder is
expected to be one of the top 2 leading causes of disabil-
ity-adjusted life years in 2020 [1]. In primary care, 10% of
the patients have a depressive disorder -although they
may not explicitly seek help for this condition- [2], and
when taken together with comorbid anxiety disorders, the
community prevalence increases to an alarming 15–20%
[2]. Moreover, up to 30% of the population will suffer
once in their lifetime from depressive or anxiety symp-
toms [2,3]. Depressive disorder has major consequences
for the lives of patients, but is treatable. However, it is fre-
quently under-diagnosed and under-treated in primary
care [4]. Hence there is clearly room for improvement in
the diagnosis and treatment of depressive disorder in pri-
mary care.
When looking at pitfalls in the efficient diagnosis and
treatment of depressive disorder in primary care, diagno-
sis is paramount for the success of the treatment. How-
ever, several barriers hamper the diagnostic process.
Patients often present themselves with several problems at
the same time, and the general practitioner (GP) has to
deal with 'competing demands', as described by Nutting
[5]. In primary care a patient-led agenda is usually fol-
lowed, and this reduces the chance of detection, because
many depressed patients tend to avoid acknowledgement
of their distress [5]. Moreover, a European study has
shown that the length of the consultation increases drasti-
cally when psychosocial problems are detected by the GP
[6]. Therefore, GPs do not always focus on the possibility
of an underlying mental disorder such as depression.
Detection is further impaired, because 70% of depressed
patients present themselves with physical symptoms and
not with depressive symptoms [7]. In addition, the
comorbidity between somatoform disorders and depres-
sion is high; earlier research shows a prevalence of 16.1%
for somatoform disorders in primary care, and a 3.3 times
greater likelihood of comorbid anxiety/depressive disor-
der than can be expected by chance [8]. Medically unex-
plained symptoms are thus, even though not by rule, at
least a possible symptom of depressive disorder, and
should therefore be addressed. Comorbid somatoform
disorder influences the outcome of treatment; comorbid
pain with depression, for example, predicts a longer time
to remission [9].
Depressive disorder with comorbid physical chronic ill-
ness is highly prevalent in primary care [10-13] and it neg-
atively influences (treatment of) the comorbid physical
illness, and vice versa [14,15]. For instance, the course of
major depressive disorder in patients with diabetes tends
to be more severe, with recurrences being the norm rather
than the exception. However, even if these patients are
treated successfully, approximately 80% will experience a
recurrence [14]. Comorbid depressive disorder is associ-
ated with a lower quality of life [16,17] poor adherence to
(diabetic) treatment [14,18] and also increased health
care costs [19,20]. Therefore, in the present study atten-
tion will be paid to comorbid somatoform disorder and
physical chronic illness as factors in the accurate diagnosis
and treatment of depressive disorder.
In primary care, evidence-based treatments for depressive
disorder are available, but these are used insufficiently,
and with miscellaneous results [4,21]. Impeding factors
are non-acceptance of the diagnosis, non-adherence of
patients to the treatment, and non-adherence of GPs [4].
Earlier research has shown that interventions developed
in the mental health setting can also be effective in pri-
mary care [22], but screening per se [23] and simple inter-
ventions [24] alone are not effective. Many single
treatment modes -for instance, pharmacotherapy, psycho-
therapy or GP training- have been tried out in primary
care, but with disappointing results; the treatment modes
are, in fact efficacious, but their effect is limited [23]. The
efficacy of a specific treatment mode is usually studied in
a controlled clinical trial, but the implementation in daily
practice under uncontrolled conditions can (and does)
lead to different and sometimes worse outcomes [23,25].
Schulberg therefore opts for ways to transfer efficacious
treatments from research settings to routine primary care
in a way that 'permits them to flourish', recommending
various steps to execute this transfer effectively [25].
Multi-faceted, patient-tailored methods of treatment are
needed, in combination with improvement of adherence,
i.e. disease-management programmes such as collabora-
tive care [24,26-29]. Two recent meta-analyses have
indeed shown the effectiveness of such collaborative care
approaches in primary care [30,31].
The collaborative care framework used in the present
study is based on enhancing active collaboration of the
patient with the providers of the treatment, and active col-
laboration between primary care and mental health care
[26,32]. Within this collaborative care framework the fol-
lowing interventions are implemented: care-management
[32,33], contracting [29] (the care manager explains the
nature of the symptoms as part of a depressive disorder,
mentions several evidence and guideline-based treatment
options, and formulates a treatment plan, together with
the patient and the GP in accordance with the preferences
of the patient), adherence-enhancing techniques, man-
ual-guided self-help and/or lifestyle changes, Problem
Solving Treatment (PST) [34-36] and antidepressant med-
ication according to a treatment algorithm. Psychiatric
consultation is one of the adherence-enhancing tech-Page 2 of 11
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patients preferences in the contracting phase, the collabo-
rative care treatment plan contains (one of) these mod-
ules. Contracting and self help are novel within this
collaborative care approach. Contracting is included
because it has been proven to be an effective way to
enhance adherence [29], and self-help because this strat-
egy has a long history of positive results in the Nether-
lands [37-40]. In Wagner's chronic care model, self-help
has always been a major aspect of good chronic illness
care, and in the IMPACT study [27,32] self-help was also
included and referred to as education for self manage-
ment. In the present study this aspect is emphasized even
more. This will be described in more detail in another
publication [41].
One of the elements in the collaborative care treatment
model is a type of evidence-based psychotherapy for
depression that is feasible in primary care. An option that
meets these requirements is PST, a brief psychological
intervention that is based on problem solving therapy
from the behavioural perspective, but is less time-con-
suming [36,42]. Research in the UK has recently shown
that PST provided by suitably trained practice nurses is
effective in the treatment of depressive disorder in pri-
mary care patients [34,35]. The IMPACT study in the USA
also successfully implemented PST within a collaborative
care approach in the treatment of depressive disorder in
primary care patients [32].
Algorithms describing the stepped use of antidepressant
medication already exist, but are mainly used in second-
ary care [43-45]. Antidepressant medication is effective in
the treatment of major depressive disorder in primary care
[46], but current practice can be further improved by
adherence-enhancing strategies according to an algorithm
that has been specifically developed for the primary care
setting. Elements of the present treatment algorithm are
specific decision points for stepped care and recommen-
dations for the choice of medication and daily dosages,
implemented by the GP and reinforced by a consultant
psychiatrist.
The aim of the current randomised clinical trial (RCT) is
to study the effectiveness of treatment for depressive dis-
order in primary care in the Netherlands based on a col-
laborative care framework, and including care
management, contracting, adherence-improving strate-
gies, manual-guided self help and lifestyle interventions,
PST, and an antidepressant treatment algorithm, in which
the treatment plan is based on patient preferences, and
compared with well-documented care as usual (CAU) as
provided by the GP.
The interventions included in the collaborative care pack-
age are all evidence-based, and the trial will test the whole
package for effectiveness in primary care (compared to
care as usual). This study is therefore a pragmatic trial, not
an efficacy trial, because it is not the intention to evaluate
new interventions [47]. Economic analyses will be per-
formed to assess whether collaborative care is not only
effective in terms of response and remission to treatment,
but also effective in terms of (health care) costs.
Methods/design
Objectives
The primary aim of the current study is to evaluate the
effectiveness of a collaborative care approach, including
contracting, PST and an antidepressant treatment algo-
rithm in the treatment of major depressive disorder in pri-
mary care. Secondary aims are to assess remission, and to
estimate the cost-effectiveness of the intervention.
Study design
The study design is a two-armed randomised pragmatic
clinical trial, stratified according to physical chronic ill-
ness.
Subjects are randomised and allocated to the intervention
(collaborative care) or the control group (CAU). See Fig-
ure 1 for flowchart of participants.
Recruitment of GPs
The study is designed in cooperation with the Department
of General Practice at the VU Medical Centre in Amster-
dam. From the group of general practices connected to
this department, as well as from general practices con-
nected to a regional support structure for primary care in
two other regions in the Netherlands, practices will be
recruited.
Recruitment of patients
The aim is to include patients with a diagnosis of major
depressive disorder and who dysfunction due to this
depressive disorder (i.e. by the loss of role-functioning in
daily life).
All patients who visited the participating practices within
the previous 6 months will be selected from the files.
These patients will receive a letter describing the purpose
of the study, together with an informed consent form for
the screening procedure, the Patient Health Question-
naire depression sub-scale (PHQ9) [48] that is used as a
screener for depressive disorder, and baseline question-
naires. Any other patients that the GPs recommend for
participation will also receive the informed consent letter,
the PHQ9 and the baseline questionnaires.Page 3 of 11
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Flowchart of participantsigure 1
Flowchart of participants. GP: general practitioner, PHQ9: Patient Health Questionnaire depression sub-scale, MINI inter-
view: Mini-International Neuropsychiatric Interview
GPs participating  
N= 40 
Randomisation
T2 questionnaires 
(6 months)  
MINI interview and  
2nd informed consent  
T3 questionnaires 
(9 months)  
T2 questionnaires 
(6 months)  
T3 questionnaires 
(9 months)  
Screening 
Partial informed consent, 
PHQ9, and baseline 
measurement 
N= 6000 to all visiting 
patients within the 
previous 6 months 
Excluded  
PHQ9 negative (<15) & 
no response
Excluded 
Less than 6 weeks 
complaints,  no 
dysfunctioning in at least 
one social role (work, 
household, relationship), 
suicidal, psychotic or 
dementia, language 
problems, drugs/alcohol 
addiction and/or already 
receiving psychiatric 
treatment 
T1 questionnaires 
(3 months)  
T1 questionnaires 
(3 months) 
Collaborative care 
N=120 
Care as usual 
N=120 
T4 questionnaires 
(12 months)  
T4 questionnaires 
(12 months)   
N=60 with 
comorbid 
chronic 
physical 
illness
N=60 with 
comorbid 
chronic 
physical 
illness
N=60 
without 
comorbid 
chronic 
physical 
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without 
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chronic 
physical 
illness
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PHQ9 and also give informed consent [48]. Subsequently,
the Mini-International Neuropsychiatric Interview (MINI
[49,50] will be administered for the classification of
symptoms and the diagnosis of major depressive disorder.
In the same interview the patients will be asked if they
have had the symptoms for at least 6 weeks, and if their
dysfunctioning leads to serious problems in at least one of
the following roles: work, household activities or relation-
ship.
In the intervention group, the patients will be invited for
a consultation with their GP; in the control group, the
patients will receive CAU.
Patient exclusion criteria
Patients will be excluded from the study if they are sui-
cidal, psychotic, or suffering from dementia, have insuffi-
cient knowledge of the Dutch language to fill in the
questionnaires, are addicted to drugs or alcohol, are
already receiving psychiatric treatment and/or are under
18 years of age.
Intervention
Training
Since the treatment includes a collaborative care interven-
tion, the participating GPs and care managers will receive
training in collaborative care, including contracting and
the antidepressant treatment algorithm. The practice
nurses will also be trained in care management and will
be trained in PST.
The training will be given by the research group. All mem-
bers of the research group had received training from the
IMPACT research group in Seattle [32], the developers of
the collaborative care model.
Treatment in the intervention group
1. Collaborative care
The care provided in the intervention group follows a col-
laborative care approach: patient-tailored care executed,
in the current study, within a team of the GP, the patient,
the care manager and the consultant psychiatrist. Within
this team the need for and the specific requirements for
treatment are assessed, and a treatment plan is developed
by the GP, the care manager and the patient. Subse-
quently, the care manager coordinates the care and evalu-
ates each step. If necessary, each treatment step is followed
up by a next step to improve the outcome according to the
principles of stepped care [51]. The care manager consults
the psychiatrist at set points in time, and if there are any
difficulties. Subsequently, the care manager advises the
GP when necessary.
2. Contracting
During the initial visit, the care manager informs the
patient about depressive disorder, and discusses treatment
options with the patient. The patient is then offered the
choice between several types of treatment (PST and anti-
depressant medication if desired) and, according to the
patient's preferences, a treatment plan is jointly formu-
lated by the care manager, the patient and the GP
together.
Initially, the progress of the patient according to the treat-
ment plan is monitored by the care manager, weekly or
fortnightly, by telephone or during visits to the clinic. The
PHQ9 is filled in, and the results are discussed. When the
symptoms are in remission, a relapse prevention plan is
formulated by the care manager and the patient together
(e.g. defining alarming symptoms and maintenance of
antidepressant medication) and follow-up becomes less
frequent.
If the patient does not respond (or responds only par-
tially) to the initial treatment, and/or if a patient is not sat-
isfied with the chosen treatment, another form of
treatment will be contracted. Subsequent steps are again
based on the patient's preferences, and follow the princi-
ple of stepped care supervised by the consultant psychia-
trist.
3. Improving adherence
The adherence of GPs has been found to be enhanced by
a combination of phone calls, written instructions and
reminders; an approach that is feasible and effective
[24,27,52]. The care manager is likewise closely moni-
tored via a net-based tracking system, with set evaluation
points every six weeks under the supervision of the con-
sultant psychiatrist. There will be PST supervision, and
monthly meetings with other care managers will be held
to improve performance as well as adherence.
Patient adherence is improved by contracting and provid-
ing written instructions for the patient [24,53] and the
care manager, who monitors the patient meticulously
[32].
4. Manual-guided self-help
One of the core symptoms of depression is the loss of
interest in (nearly) all activities during the best part of the
day, almost every day [54]. In order to relieve these symp-
toms, a self-help manual has been developed, activating
the patients step-by-step as they read each chapter. Ini-
tially, the patients are encouraged to participate in low-
level behavioural activation, depending on their capabil-
ity. Attention is paid to restoring the sleep-wake-rhythm
[55], self-relaxation-techniques [37,56] and diet [40,57].
As the patient improves, there are options for running-Page 5 of 11
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helpful in the treatment of (minor) depressive disorder,
and promoting return to work. Two-thirds of the costs
involved in the treatment of depressive disorder are
accounted for by absence from work through illness, as
Bosmans recently pointed out [59].
5. Treatment algorithm for antidepressant medication
To enhance the effectiveness of and adherence to antide-
pressant medication, the GPs are provided with a protocol
of instructions to optimize the prescription of antidepres-
sants. The protocol includes time to titrate to daily dos-
ages (2 weeks), time to respond (partially or remission,
another 4 weeks), and well-defined step up criteria and
methods (for example 'partial response: increase dose',
'no response: switch medication'). Progress (i.e. (partial)
response) is measured with the PHQ9, and results and
adverse effects are discussed with the care manager. Sub-
sequently, the care manager advises the GP to step up the
treatment (if necessary, after consulting a psychiatrist) if
the results are not satisfactory and/or adverse effects are
intolerable.
6. Problem solving treatment
PST is provided by the care manager in a course of 6–12
sessions, depending on the progress on the PHQ9 scale.
The problem solving approach consists of 7 stages, and is
based on the concept that emotional problems are often
induced by problems in daily life [35]. The focus lies on
regaining control over symptoms by doing something
about these problems. The first session lasts for one hour,
during which, based on the patient's current problems a
clear focus of the treatment is established. Follow-up ses-
sions last for 30 minutes.
Stepped care is realized by evaluation points at 6 weeks
and 12 weeks at which it is decided if one or two antide-
pressants, and 6 sessions or 12 sessions of PST will be suf-
ficient treatment, depending on the improvement
according to the PHQ9. It is possible to switch between
the two options (e.g. due to disappointing results, or
adverse effects) or, if the patients prefers this, to receive a
combination of the two treatment options. Either way, the
total intervention will last for 18 weeks. This is the maxi-
mum duration of the studied intervention.
Treatment in the control group
Half of the general practices function as a control group,
and in these practices the patients receive CAU. The actual
content of the CAU treatment (e.g. medication, number of
contacts in primary care, and referral policy) will be
assessed with the Scale for Medical Utilisation of Health
Services [53].
Outcome-parameters
1. Primary outcome measure
Response
The severity of the depressive symptoms is measured with
the Patient Health Questionnaire depression sub-scale,
[48] a brief but valid instrument that scores each of the
DSM-IV criteria for major depressive disorder. Response is
defined as a 50% reduction of symptoms [48].
2. Secondary outcome measures
Remission of depressive symptoms
Remission -reduction of DSM-IV criteria below the thresh-
old for a diagnosis of depressive disorder- [54] is meas-
ured with the PHQ9 [48]. As in previous studies
[32,48,60], remission is defined as a score between 0 and
4 on the PHQ9.
Cost utility
In addition to the improvement in the severity of symp-
toms, the cost utility of collaborative care compared to
CAU is also assessed. Therefore, the direct medical costs
and the costs due to production losses (productivity costs)
will be estimated. The relevant data will be collected by
means of the Trimbos/iMTA questionnaire for Costs asso-
ciated with Psychiatric Illness (TiC-P) [61,62]. Quality of
life is assessed with the EuroQol (EQ-5D) [63] and the
Short Form-36 (SF-36) [64], which are validated tools for
measuring general health-related quality of life.
The EQ-5D descriptive system consists of five dimensions
(Mobility, Self Care, Usual Activities, Pain/Discomfort
and Anxiety/Depression) each with three levels (no prob-
lems, some problems and extreme problems), thus defin-
ing 243 (35) distinct health states. Recently, a study in the
Netherlands measured and valuated the EQ-5D in a
national setting, resulting in the 'Dutch EQ-5D tariff'. The
resulting tariff is used to calculate utilities for EQ-5D
health states for cost-utility analyses ofDutchhealth care
programmes and treatments.
The cost utility is evaluated by relating the difference in
direct medical costs per patient receiving collaborative
care or CAU to the difference in terms of Quality Adjusted
Life Years gained (QALY), which yields a cost per QALY
estimate. Furthermore, an attempt will be made to esti-
mate the cost per QALY, including the productivity costs.
3. Effect modifiers and additional outcome measures
Effect of physical illness. Physical comorbidity is meas-
ured by means of a questionnaire developed by the Dutch
Central Bureau for Statistics (the CBS list). The list con-
tains 28 chronic conditions (e.g. diabetes type II and Mul-
tiple Sclerosis). Physical illness is thought to be the key
effect modifier.Page 6 of 11
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Klachten Vragenlijst: Bodily Complaints Questionnaire
(LKV; assessing the number and intensity of functional
somatic complaints a patient is experiencing) [65], the
Screening for Somatoform Symptoms-7 (SOMS-7; meas-
uring possible comorbid somatoform disorder) [66], the
Illness Attitude Scale (IAS; measuring concern about dis-
ease) [67] and the Whitely Index (measuring Hypochon-
driasis) [67].
Concomitant symptoms of comorbid chronic illness,
measured with the Multidimensional Fatigue Inventory
(MFI) [68,69], and the World Health Organization Disa-
bility Assessment Survey II (WHO-DAS-II) [70].
Depressive symptoms are assessed as well with the 30-
item Inventory for Depressive Symptomatology Self-
Report (IDS-SR) [71]. The IDS-SR measures all DSM-IV
criteria for the diagnosis of major depressive disorder, as
well as the symptoms that are most frequently associated
with major depressive disorder (e.g. melancholic symp-
toms and anxiety) [72].
Preference and adherence. Possible patient preference is
based on the preferences of patients in the intervention
group, patient adherence is assessed with a qualitative
questionnaire, and the patient-doctor working relation-
ship (from the perspective of the patient) is assessed with
the Patient Doctor Relationship Questionnaire (PDRQ-9)
[73]. The attitude of the GP towards the treatment of
depressive disorder is measured with the Depression Atti-
tude Questionnaire (DAQ) [74].
Life-events and social support are measured according to
the Social Readjustment Rating Scale [75] and two items
of the SF-36 [64], respectively.
Personality is assessed with the Neuroticism extraversion
openness-five factor inventory (NEO-FFI; sub-scales
'extraversion' and 'neuroticism') [76,77].
Treatment in the CAU group is assessed with the Contact
between Patients and Practitioners Questionnaire (filled
in by the patient) and the Questionnaire Medical Con-
sumption (filled in by the GP) [53].
Baseline measurements take place before inclusion (T0),
and follow-up measurements take place after 3 months
(T1), 6 months (T2), 9 months (T3) and 12 months (T4). 
Sample size
The primary outcome measure is response (a 50% reduc-
tion in depressive symptoms). Based on previous work
[27] the expected response rate is 14,76% in the CAU
group and 31,8% in the intervention group. Given these
estimates of the effect of the intervention, and using con-
ventional values for α (0.05) and β (0.80), and two-tailed
tests with equal groups, the sample size aimed for in the
current study is 94 patients per arm. To compensate for an
estimated 26% loss to follow up, 120 patients per arm will
be included. (See Figure 1 for flowchart participants.
Analysis
Intention-to-treat analysis will be performed with t-tests,
Chi-square tests (dichotomous variables), and General
Linear Model (GLM) repeated measurements (continuous
variables). The effect size will be estimated by Chi-square
tests, and described in Cohen's d. Time to remission will
be analysed using survival analysis, and Cox regression
models for multivariate analyses will be used for possible
effect modifiers (e.g. physical chronic illness and somato-
form disorder). Possible confounders such as age, gender,
immigrant status, level of education, history of treatment
and life events will also be included as variables in these
analyses.
Economic evaluation
The aim of the economic evaluation is to assess the cost-
effectiveness of collaborative care of the treatment of
depressive disorders in primary care. A cost-utility analysis
(CUA) will be applied, and the results will be expressed as
cost per QALY. The economic evaluation will be under-
taken from a societal perspective. Hence, all relevant
effects and costs due to resource utilisation within the
health care system (direct medical costs) and costs due to
production losses (productivity costs) will be included.
Since the collaborative care intervention used in this study
is a new intervention, a unit price per session is not known
yet. To determine a reference price, a detailed cost-price
study will be performed. Therefore, we will perform meas-
urements of time for face-to-face contacts as well as indi-
rect time per contact (e.g. consultations of other
specialists) for a total of 20 sessions. Furthermore, we will
estimate overhead costs based on the information of the
financial department of the hospital. This will result in an
estimate of the actual costs per contact. The unit cost esti-
mate per contact will be used as a reference price per con-
tact for the collaborative care intervention.
The TiC-P [61] will be used to assess the costs. The TiC-P
is commonly applied in the economic evaluation of treat-
ment in mental health care. For instance, the TiC-P was
recently used in a large naturalistic trial on the cost utility
of brief psychological treatment for depression and anxi-
ety [62].
To calculate the total direct medical costs, the total
number of medical contacts (outpatient visits, length of
stay in hospital, use of medication, etc will be multipliedPage 7 of 11
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Reference unit prices of health care services will be
applied, and adjusted to the year of this study according
to the consumer price index [78].
In the second part of the TiC-P a short form of the Health
and Labour questionnaire (HLQ) will be used to collect
data on productivity losses [79]. The Short-Form HLQ
(SF-HLQ) consists of three modules that measure produc-
tivity losses: absence from work, reduced efficiency at
work and difficulties with job performance [80]. The
number of days absent from work and the actual cost of
hours missed at work due to health-related problems are
calculated from the average value added per worker
according to age and gender per day and per hour, respec-
tively. If respondents indicate that they have been absent
from work for the entire recall period, data will be col-
lected as from the date when the period of long-term
absence started. This additional information will be used
to calculate the production losses according to the friction
cost method [81,82]. The friction cost method takes into
account the economic circumstances that limit the losses
of productivity to society, which is related to the fact that
a formerly unemployed person may replace a person who
becomes disabled [81].
For the economic evaluation, the effects will be measured
by calculating utility scores. In addition to the clinical out-
come parameters, utility scores will supply additional
information about the impact of collaborative care on the
treatment of depressive disorder, compared to CAU on the
general health-related quality of life. Furthermore, the
results can be compared to a broad range of other health
care interventions, also outside the mental health care set-
ting.
The cost utility will be evaluated by relating the difference
in direct medical costs per patient receiving collaborative
care or CAU to the difference in terms of QALYs gained,
which yields a cost per QALY estimate. Furthermore, the
cost per QALY, including the productivity costs, will be
estimated.
In the case of missing data on costs and/or effects, and the
additional uncertainty this introduces, multiple imputa-
tion will be used [83]. The Monte Carlo Markov Chain
(MCMC) approach will be used to impute the missing val-
ues. The uncertainty will be assessed using bootstrapping,
and the results will be presented in acceptability curves
[84].
Time-frame of the study
The preparatory period is 6 months. Subsequent to the
approval of the Medical Ethical Board, general practices
will be recruited and the GPs and care managers will be
trained. The inclusion and intervention phase will take 22
months. The follow-up phase will be 6 months, and the
data-analyses will last for 6 months. The entire study
period will last for 4 years.
Ethical principles
The study has been designed, and will be executed in
accordance with the principles laid down in the Helsinki
Declaration (Edinburgh, Scotland amendment, October
2000).
Participation in the study is voluntary, and written
informed consent will be obtained. The patients will be
explicitly informed of the fact that they can withdraw their
consent to participate at any time, without specification of
reasons and with no negative consequences with regard to
their future medical treatment. Patients who wish to with-
draw from the study will receive care as usual.
The study protocol has been approved by the Medical Eth-
ics Committee of the VU Medical Centre.
Discussion
The aim of this study is to investigate the effectiveness of
an American model of collaborative care for the treatment
of depression, implemented in the Netherlands. The
emphasis lies on collaboration with a care manager, team
effort and stepped care. Trials on such disease manage-
ment programmes have so far shown promising results in
the USA and the UK respectively [23,33,85-87], and are
also likely to show the same results in the Netherlands.
The focus hereby lies on major depressive disorder, since
disease management programmes are developed to treat
chronic diseases [32,88], and major depressive disorder
closely resembles a chronic disease in terms of difficulty to
treat, impact on daily life, duration, and chance of relapse
[2].
Strengths and limitations
Critics may raise concern about whether collaborative care
-as designed in the USA- can be effectively implemented
in the Netherlands, since the health care systems differ
between the two countries. The American health care sys-
tem is based on the comparatively rare private enterprise
health care system (i.e. decentralized payment) whereas
in the Netherlands there is a public insurance system (i.e.
centralized payment). Primary care in the Netherlands is,
in the majority of cases, provided in very small practices
(1–2 GPs), and is in many ways less organized and less
centralized than thelarger group practices in the USA. This
could present a challenge in the implementation of a
team-based approach with a care manager, because it is
not likely that a solo general practice can really afford to
have a full-time care manager, so the care managers will
probably also have several other practice tasks. However,Page 8 of 11
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several settings, with different health care providers and
different levels of CAU [32], and in each setting significant
improvement has been reported for the collaborative care
approach compared to CAU [27,30,31,89]. One can
therefore expect to find the same improvement when the
collaborative care approach is carefully implemented in
the Netherlands.
A possible limitation of the study might also be that we
are adding two elements, i.e. self-care (a self-help manual
has been developed for this trial, enhancing patient
empowerment) and contracting, in which the weighing of
patient preferences for a given treatment is crucial. This
might make the intervention stronger, but it might also
make implementation more strenuous. Therefore, specific
emphasis will be laid on adherence to these two addi-
tional aspects of the model.
Due to randomisation at patient level, one can argue that
contamination of effect could occur: GPs and care manag-
ers might transfer their knowledge of the intervention to
the control group. The risk of dilution of effect however,
is expected to be very small. The positive effect of the inter-
vention can only be reached by implementing the whole
package, including the care manager who plays the most
significant role within the model, and patients receiving
care as usual are not involved with a care manager. The
antidepressant treatment algorithm will be carried out by
the GPs and not the care manager, but under strict super-
vision of the consultant psychiatrist, so dilution of effect
in the control group, when medication is concerned, is
also expected to be small.
A characteristic of collaborative care is the fact that the
offered treatments are all evidence-based; efficacy thus has
previously been proved. Effectiveness trials and reviews
have already shown mixed but positive results concerning
the optional treatment modes: short-term psychotherapy
and antidepressant medication if desired. Either no signif-
icant difference is found between the effectiveness of anti-
depressant medication and psychotherapy [90-92] or, a
combination of antidepressant medication and some
form of psychotherapy is most effective [91,93]. A strong
aspect of this design is the fact that we are offering both
evidence-based treatment modes in a package.
Strengths and limitations taken into account, at the very
least patients make a significant contribution to (the
choice of) the treatment in this design. Aiming, above all
else, to relieve patients of the burden of depressive disor-
der, this seems a particularly valuable contribution to the
design.
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